Erythropoietin and iron.

摘要: Careful evaluation of iron status is pivotal importance in end-stage renal disease patients before and during r-HuEPO therapy. Absolute (ferritin 5%) deficiency are the main reasons for hyporesponsiveness. Adequate supplementation allows significant reduction dosage costs. Oral recommended predialysis peritoneal dialysis with serum ferritin > 100 micrograms/l, whereas i.v. therapy choice hemodialysis patients. However, neutrophil impairment other possible side-effects (e.g. cardiovascular complications, malignancy) as a result suggest that overtreatment should be avoided.